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1  | INTRODUC TION
Haematopoietic stem cell transplantation (HSCT) is a potentially 
curative treatment for malignant and non- malignant diseases. An 
HSCT can be performed either with autologous or allogeneic stem 
cells. In an autologous HSCT, patient’s own stem cells are collected, 
stored and reinfused after suppressing the immune system with 
high- dose chemotherapy. For example, high- dose melphalan (HDM) 
is the standard care treatment regimen for multiple myeloma (MM) 
(Voorhees & Usmani, 2016).
A common adverse effect of HDM is oral mucositis (OM), 
characterized by pain, erythema, swollen mucosa, xerostomia 
and ulcerations (Peterson & Cariello, 2004). Severe OM requires 
narcotics and parenteral feeding and increases hospital stay. 
Furthermore, the ulcerative lesions may allow the penetration 
of bacteria into the bloodstream resulting in a systemic infec-
tion (Peterson & Cariello, 2004). Oral mucositis to some degree 
affects almost all patients treated with high- dose chemother-
apy. A multicentre study to assess the incidence, severity and 
duration of OM found that 90% of the MM patients treated with 
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Objective: One explorative observational study in two parts was performed to ex-
amine early salivary changes in relation to oral mucositis (OM) in multiple myeloma 
patients treated with high- dose melphalan and autologous haematopoietic stem cell 
transplantation (HSCT). As cryotherapy was introduced after part A as regular care, 
its effect on OM could be evaluated.
Methods: Unstimulated whole- mouth saliva (UWS) and stimulated whole- mouth sa-
liva (SWS) were collected, and OM was scored with the Oral Mucositis Nursing 
Instrument (OMNI) at days −3, 0, 4, 7, 11 and 14 after HSCT. Salivary flow rate, total 
protein (BCA), mucin 5B, albumin (western blot), total IgA, lactoferrin and myeloper-
oxidase levels (ELISA) were determined.
Results: Trends of decreasing UWS and SWS flow rates and total IgA levels were 
observed. At days 7 and 11, increases in lactoferrin and albumin levels were found in 
UWS and SWS. A positive correlation was found between OMNI scores and albumin 
and lactoferrin levels in SWS (R2 = .56, p = .029 and R2 = .49, p = .043, respectively). 
In part B, cryotherapy significantly lowered peak OMNI scores.
Conclusion: Compositional changes in saliva reflecting inflammation were found in 
the first days after HSCT, and the use of cryotherapy in the second part was associ-
ated with decreased OM severity.
K E Y W O R D S
haematopoietic stem cell transplantation, multiple myeloma, oral mucositis, saliva
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HDM and autologous HSCT was affected. Severe OM (WHO 
score 3 and 4) occurred in 46% of the MM patients and had 
a duration of 5 days (Blijlevens et al., 2008). Peak OM scores 
were found approximately 9 days after HSCT (Blijlevens et al., 
2008). To prevent OM, cryotherapy is used for patients under-
going HDM and HSCT (Marchesi et al., 2017). Cryotherapy, the 
use of ice chips during the infusion of chemotherapy, results 
in local vasoconstriction, which reduces the amount of onco-
lytic drugs that reach the oral mucosa. Although it significantly 
reduces the incidence, some patients still develop severe OM 
(Marchesi et al., 2017). Moreover, there are no good treatment 
options for OM.
One factor that may influence the severity of OM is a de-
crease in the normal defence mechanisms in saliva (Epstein, 
Tsang, Warkentin, & Ship, 2002). Several salivary constituents 
are thought to have a protective function such as immunoglobu-
lins, histatins, cystatins, defensins and lactoferrin (Amerongen & 
Veerman, 2002). A study evaluating changes in the salivary pro-
teome after allogeneic HSCT found that levels of lactoferrin and 
secretory leucocyte protease inhibitor were increased at 6 months 
compared to pre- HSCT levels (Imanguli et al., 2007). The levels of 
secretory IgA (sIgA) were decreased 1 month after HSCT, but re-
turned to pre- HSCT levels 6 months after HSCT (Imanguli et al., 
2007). Decreased sIgA levels after HSCT were also found in an-
other study examining salivary changes in MM patients undergo-
ing autologous HSCT (Avivi et al., 2009). In the latter study, sIgA 
levels were significantly reduced 7 days after HSCT and OM was 
associated with a decrease in sIgA, uric acid levels and salivary 
antioxidant activity.
As OM is most severe around 9 days after transplantation, 
the aim of this study was to examine early salivary changes in 
relation to OM in MM patients treated with HDM and autologous 
HSCT. To determine salivary changes caused by leakage from 
the oral mucosae, unstimulated whole-mouth saliva (UWS) and 
stimulated (SWS) whole-mouth saliva were used in this explor-
ative observational study performed in two parts. Due to proto-
col changes in regular care at the hospital based on the MASCC/
ISOO clinical practice guideline in 2014 for the prevention of 
OM, patients in the last part received cryotherapy during infu-
sion of HDM (Lalla et al., 2014).
2  | MATERIAL S AND METHODS
An explorative observational study in 2 parts was performed in 
2013 (part A) and 2015 (part B). Approval was given by the Local 
Ethical Committee (registration number 2012/528), which stated 
that this research was not subjected to the law governing research 
involving human subjects and no approval of the Local Ethical 
Committee was necessary. The study was conducted in full accord-
ance of the World Medical Association (2001). All patients were 
informed about the study and signed informed consent before par-
ticipating in the study.
2.1 | Study population
Adult MM patients undergoing HDM (200 mg/m2, infused dur-
ing 1 hr) and autologous HSCT at the Department of Hematology 
of the Radboud University Medical Centre were asked to partici-
pate. Patients who did not understand the Dutch language were 
excluded. In total, 12 (of 18) eligible patients were included from 
March 2013 to October 2013 for the first part (A) and 8 (of 11) 
eligible patients were included from May 2015 to July 2015 for the 
second part (B).
Patients brushed their teeth 4 times a day and rinsed with 
physiological salt solution when required per standard protocol. 
To maintain fluid balance during admission, patients received 
intravenous NaCl 0.9% solution. Analgesics, parenteral feed-
ing and other medications were administered if necessary per 
standard protocol. In the second part, cryotherapy was used 
by consuming ice chips or crushed ice starting 5 min before 
HDM infusion (day −2) until 30 min after infusion. Melted ice 
was swallowed or spit out before the use of new ice chips. The 
medical charts were used to obtain the neutrophil counts and 
albumin levels in blood and to obtain the administered dose of 
melphalan in mg/kg.
2.2 | Oral examination and saliva collection
During the hospitalization period, saliva was collected and the sever-
ity of OM was scored using the OMNI score (Oral Mucositis Nursing 
Instrument) on day −3 (admission day), day 0 (day of autologous 
HSCT), day 4, day 7, day 11 and day 14 (Potting, Blijlevens, Donnelly, 
Feuth, & van Achterberg, 2006). The total OMNI score was calcu-
lated by the sum of the individual scores (ranging between 0 and 
3) for erythema, edema, ulcerations, pain, mouth dryness and saliva 
viscosity.
The protocols for the collection of UWS and SWS were 
based on the guidelines for saliva collection of the University 
of Southern California School of Dentistry (Navazesh & Kumar, 
2008). For the collection of UWS and SWS, patients were asked 
to refrain from eating or drinking 1 hr before collection and to 
swallow immediately before collection. For UWS, patients were 
asked to spit the saliva in a previously weighed plastic cup for 
5 min without making any effort to increase the saliva flow. For 
SWS, patients were asked to chew 1 min on a piece of paraffin 
film to stimulate saliva flow. After swallowing, SWS collection 
was started by spitting saliva, while continuing chewing, in a 
plastic cup for 2- 5 min. Directly after collecting, samples were 
weighed and stored on ice. UWS and SWS flow rates were esti-
mated by assuming 1 ml of saliva is 1 gram. Directly after collec-
tion, pH was determined using pH strips (pH- indicator strips 4.0 
– 7.0, Merck®, Germany), and saliva samples were centrifuged 
for 5 min at 9,800 g (mini spin plus, Eppendorf, Germany). The 
supernatant was stored separately from pellets at −80°C. For 
analysis, samples were defrosted and divided into aliquots and 
stored at −80°C.
974  |     van LEEUWEn Et aL.
2.3 | Saliva analysis
Total protein was determined using the BCA protein assay kit ac-
cording to the manufacturer’s protocol (Pierce™ BCA protein assay 
kit, Thermo Scientific, USA). Salivary proteins and glycoproteins 
were analysed by SDS- PAGE gels stained with Coomassie Brilliant 
Blue R250 (CBB) and Periodic Acid- Schiff (PAS) to determine mucin 
5b (MUC5B). Western blotting was used to determine MUC5B and 
albumin levels, and enzyme- linked immunosorbent assay (ELISA) 
was used to determine total IgA, myeloperoxidase (MPO) and lacto-
ferrin levels.
2.4 | SDS- PAGE and CBB/PAS staining
For SDS- PAGE gels, equal amounts of total protein were loaded onto 
gels, UWS and SWS separately. Samples were prepared in LDS con-
taining sample buffer (1:4) and DTT (1:10), incubated at 95°C and 
centrifuged. Protein standards with predefined molecular weights 
(5 μl, SeeBlue® Plus2 prestained protein, Thermo Scientific, USA) 
and 10 μl of sample were loaded on 4%- 12% Bis- Tris gels (NuPage™, 
Thermo Scientific, USA) and run in MES SDS running buffer as per 
manufacturer’s recommendations. Gels were stained in CBB staining 
solution (Brilliant Blue R Staining Solution in 10% acetic acid, Sigma- 
Aldrich, UK) and destained in 10% acetic acid. The CBB- stained gels 
(after photographing) were used for PAS staining after 1 hr incuba-
tion in fixing solution (25% methanol, 10% glacial acetic acid in H2O). 
After incubation, gels were washed with H2O for 20 min, oxidized in 
2% periodic acid for 15 min, washed with H2O twice and incubated 
in Schiff reagent (VWR® Prolabo®, UK). Images were taken and band 
intensities were determined using a Bio- Rad® Chemidoc™ Imaging 
system and Image Lab™ software.
2.5 | Western blots
Using a sandwich technique, proteins were transferred from gel to 
a nitrocellulose membrane (Invitrogen, XCell II™ Blot Module, USA) 
in transfer buffer (Novex® NuPage Transfer Buffer 20x, USA, in 
methanol and H2O) for 1 hr at constant voltage. After transfer, the 
membrane was blocked in 5% skimmed milk in TBS- T. Blots were in-
cubated with primary mouse monoclonal anti- human MUC5B (1:500 
in TBS- T, Abcam, Ab105460, UK) or mouse anti- albumin (1:1,000 in 
TBS- T Sigma, A6684, UK). Blots were washed 3x 5 min with TBS- T 
and incubated with second antibody, polyclonal goat anti- mouse 
HRP (1:2,000 in TBS- T, Dako P0447, UK). Results were visualized 
using a chemiluminescence Western blotting reagent (Bio- Rad® 
ClarityTM Western C Kit Western ECL Subrate, USA). Images were 
taken, and intensities were determined using Chemidoc and Image 
Lab™ software.
2.6 | Sandwich ELISA
Ninety- six well plates were coated overnight at 4°C (MPO at RT) 
with 100 μl rabbit anti- human IgA (1:1,000 in Na2CO3 buffer pH 9.6, 
Dako A0262, UK), rabbit anti- human lactoferrin (1:2,000 in Na2CO3 
buffer pH 9.6, Abcam Ab15811, UK) or MPO coating antibody (1:180 
in PBS, Duoset DY3174, R&D systems, UK). The first antibody solu-
tion was discarded, and plates were washed 3x with PBS- T. Blocking 
with 300 μl of PBS with 1% BSA (1 hr at RT) was performed for MPO. 
After washing, 100 μl samples/standard was added in duplo to the 
plates and incubated at 37°C for 2 hr. IgA from colostrum I2636 (1 – 
0.0156 μg/ml in PBS- T, Sigma- Aldrich, UK), lactoferrin from human 
milk L0520 (125 – 1.95 ng/ml in PBS- T, Sigma- Aldrich, UK) and MPO 
standard (16 – 0.25 ng/ml in PBS + 1% BSA, Duoset DY3174, R&D 
systems, UK) were used as standard. For total IgA and lactoferrin, 
samples were diluted 1:50 – 1:800 in PBS- T. For MPO, samples were 
diluted 1:20 – 1:400 in PBS + 1% BSA. After incubation, plates were 
washed 3x with PBS- T and incubated at 37°C for 1 hr (total IgA and 
lactoferrin) or at RT for 2 hr (MPO) with 100 μl of polyclonal anti- 
human IgA/HRP (1:4,000 in PBS- T, Dako 0216, UK), polyclonal rab-
bit anti- human lactoferrin/HRP (1:25000 in PBS- T, Abcam ab24264, 
UK) or detecting antibody (1:180 in PBS + 1% BSA, Duoset DY3174, 
UK). For MPO, plates were washed with PBS- T and incubated with 
100 μl HRP solution (1:200 in PBS + 1% BSA, Duoset DY3174, UK) 
for 30 min at RT. After incubation with the second antibody or HRP 
solution, plates were washed with PBS- T and were incubated with 
100 μl TMB (TMB liquid substrate system, Sigma- Aldrich, UK) for 
30 min at RT in dark. Reaction was stopped with 50 μl 2 m sulphu-
ric acid, and plates were read using a microplate reader at 492 nm 
(iMark™ Microplate Absorbance Reader Bio- Rad®, USA). Protein 
concentrations were calculated with Excel software using the stand-
ard curve.
2.7 | Data analysis
Statistical analysis was performed in SPSS (version 22) and R (ver-
sion 3.4.0), and p < .05 was considered as statistical significant. 
Descriptive analysis was used for patient characteristics. To test the 
difference between the OMNI scores in part A and part B, a multi-
level regression model was used with the OMNI score as depend-
ent variable and “study part” as independent variable. To model the 
changes over time, both T and T2 were included as independent vari-
ables as well, while a random intercept was added to the model to 
allow for the clustering of measurements within patients.
All quantitative results of MUC5B, albumin, total IgA, lactoferrin 
and MPO are based on part B only, as part A was used to optimize 
the protocols for quantitative analysis of saliva samples. Results 
from the salivary compositional analysis of the first part (A) were 
only used to compare trends between both studies. To correct for 
interindividual variation between patients, scaled scores were calcu-
lated per variable per patient by subtraction of day −3 score and di-
viding by the SD. These scaled scores were used for paired t tests to 
compare days 0, 4, 7, 11 and 14 with day −3. Differences are graph-
ically labelled at α- levels of 5%, 1% and 0.1% separately to allow for 
evaluation of significance in view of multiple testing. For easier inter-
pretation, most figures contain the absolute values. Correlations be-
tween peak OMNI scores and salivary parameters were calculated 
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by applying meta- analytical techniques (inverse variance weighting) 
on the individual correlations within patients over time.
3  | RESULTS
3.1 | Patient characteristics
In total, 20 patients were included (part A: n = 12, part B: n = 8). No 
important differences in study population were observed between 
both groups (Table 1). Due to hyposalivation or nausea, it was not 
possible to collect saliva from all patients on all study days. This re-
sulted in missing samples with a peak at day 7 in both parts (Figure 1).
An important difference between both groups is the use of 
cryotherapy during the infusion of HDM in the second part (B). This 
resulted in significantly lower total OMNI scores in part B (95% CI 
[−3.87, −1.29], p < .001; Figure 2). Peak OMNI scores were seen at 
day 7 after HSCT, and the individual OMNI variables, mouth dry-
ness and edema, contributed most to the total OMNI score each day 
(Figures 2 and 3). The highest individual OMNI scores for pain and 
lesions were found in part A (Figure 3).
TABLE  1 Patient characteristics
First study 
(n = 12)
Second study 
(n = 8)
Gender (% male) 58.3% 62.5%
Age (median) 63 63
Range 43 – 68 53 – 67
Dentition (% dentate) 75% 62.5%
Melphalan doses in mg/kg 
(mean ± SD)
4.96 ± 0.60 4.65 ± 0.86
Median 4.96 4.88
F IGURE  1 Percentage of missing samples over time for 
unstimulated whole-mouth saliva (UWS), stimulated whole- mouth 
saliva (SWS) and total (UWS + SWS) for part A (grey lines) and part 
B (black lines)
F IGURE  2 Total Oral Mucositis Nursing Instrument (OMNI) 
score. Mean ± 95% CI of total OMNI score for part A (grey line) and 
part B (black line). Numbers in the graph represent the number of 
patients per time point for part A (grey) and part B (black). Total 
OMNI scores in part B were significantly lower compared to part B 
(95% CI [−3.87, −1.29], p < .001)
F IGURE  3 Contribution of four Oral Mucositis Nursing 
Instrument (OMNI) variables to total OMNI score per day. For each 
variable, mean score ± 95% CI is shown for part A (a) and part B (b)
(a)
(b)
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3.2 | Salivary flow rate, pH and total protein
Both parts showed similar changes in flow rate reductions for UWS 
and SWS over the study period, with generally flow rate levels being 
lower in part A (Figure 4a and b); especially for SWS, both parts con-
sistently showed reduced flow rates at days 0, 4, 11 and 14, compared 
with day −3. The reductions were most clear in part B: SWS flow rate 
was significantly decreased at days 0, 4, 11 and 14 compared to day 
−3, 95% CI of scaled scores [−2.01, −0.84], p < .001; [−2.14, −0.77], 
p = .002; [−2.53, −1.96], p < .001; [−2.57, −1.37], p < .001, respec-
tively. Salivary pH was determined directly after collection, showing 
a similar immediate reduction in UWS and SWS in part A and B at day 
0 as seen in the flow rates: 95% CI of scaled scores [−2.11, −0.09], 
p = .038; [−2.51, −0.52], p = .009; [−2.57, −0.65], p = .008; [−2.18, 
−0.24], p = .023, for UWS and SWS part A and part B, respectively 
(Figure 5).
Although there is some indication of increasing total protein 
levels in both parts of the study, the effect is only consistent and 
statistically significant in SWS at day 0: 95% CI of scaled scores 
[0.92, 2.18], p < .001 for part A and [0.47, 2.37], p = .011 for part B 
(Figure 6).
3.3 | Salivary composition
3.3.1 | MUC5B + albumin
Figure 7a- c shows the changes in UWS and SWS MUC5B and 
albumin levels over time with a representative CBB- and PAS- 
stained SDS- PAGE and Western blot for MUC5B and albumin 
from one patient. Although in part A an increasing concentra-
tion of MUC5B was observed in UWS, this was not confirmed 
in part B (Figure 7b). Albumin levels showed a clear trend for 
both UWS and SWS, mimicking the curve of OMNI scores. 
The albumin levels were significantly increased at day 7 in 
UWS and day 11 in SWS: 95% CI of scaled scores [0.57, 2.77], 
p = .018 and [0.61, 2.09], p = .005, respectively (Figure 7c). 
The albumin levels in blood showed a decreasing trend over 
time with lowest levels between days 9 and 10 after HSCT 
(Figure 7d).
3.3.2 | Total IgA, lactoferrin and MPO
Figure 8a- c shows the changes in UWS and SWS levels of total IgA, 
lactoferrin and MPO over time. A trend for decreasing and recover-
ing concentration is seen in UWS and SWS total IgA levels; however, 
only at day 14 in UWS, the decrease was found statistically signifi-
cant: 95% CI of scaled scores [−2.44, −0.23], p = .032 (Figure 8a). 
For lactoferrin, from day 4 an increasing trend was observed, which 
is almost parallel in UWS and SWS. The peak increase at day 11 is 
highly significant in both UWS and SWS: 95% CI of scaled scores 
[1.74, 2.56], p < .001 and [1.97, 2.58], p < .001, respectively. The pre-
liminary part A showed similar trends for total IgA and lactoferrin. 
For MPO, a fluctuating trend is seen with only limited statistical sig-
nificance of differences observed.
Myeloperoxidase was used as an indirect measurement for the 
polymorphonuclear leucocyte (PMN) levels in saliva. The PMN 
levels in blood are shown in Figure 8d. During the whole study pe-
riod, a similar trend was observed between both parts. At day 0, an 
increase in PMN levels in blood was seen while the MPO levels in 
UWS were decreased. Directly after this increase in blood PMNs, 
a decreasing trend is seen reaching undetectable levels at day 6 
after HSCT as expected (Figure 8c and d). At day 4, MPO levels in 
UWS showed an increase compared to day 0, while the PMN levels 
in blood were decreased compared to day 0 (Figure 8c and d). At 
day 7, no PMNs were detected in blood and the lowest MPO levels 
in UWS were found. Interestingly, the UWS MPO levels started 
to increase at day 11, while the PMNs were still undetectable in 
blood (Figure 8c and d).
F IGURE  4 Mean ± 95% CI of unstimulated whole-mouth saliva (UWS) (a) and stimulated whole- mouth saliva ( SWS) (b) flow rate over 
time for part A (grey lines) and part B (black lines). Numbers in the graphs represent the number of patients per time point for part A (grey) 
and part B (black). Significance levels are based on paired t tests with scaled scores all compared to day −3, *p < .05, **p < .01 and ***p < .001
(a) (b)
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3.4 | Correlations
Correlations between OMNI scores and salivary parameters are 
shown in Table 2. A positive correlation was found between total 
OMNI scores and SWS MUC5B, SWS albumin and SWS lactoferrin 
levels (R2 = .318, p = .043; R2 = .56, p = .029 and R2 = .49, p = .043, 
respectively). In addition, total OMNI scores and UWS albumin lev-
els were close to a statistical significant positive correlation (R2 = .47, 
p = .05), and total OMNI scores and SWS flow rate were close to a 
statistical significant negative correlation (R2 = −.39, p = .089).
As oral dryness is the largest contributor to OMNI scores in 
this study (Figure 2b), correlations were also determined between 
the dryness component of the OMNI score and flow rate and 
MUC5B levels in UWS and SWS (Table 2). A negative correlation 
was found between UWS flow rate and the dryness component 
of the OMNI score (R2 = −.57, p = .003), and a positive correlation 
was found between SWS MUC5B levels and the dryness compo-
nent of the OMNI score (R2 = .51, p = .015), indicating that the in-
creased feeling of a dry mouth starting from day 0 was correlated 
with the trend of increasing SWS MUC5B levels between days 0 
and 7.
4  | DISCUSSION
This study was performed to determine early changes in salivary 
parameters in relation to OM in MM patients undergoing autolo-
gous HSCT. After HSCT, salivary albumin and lactoferrin levels 
were increased, whereas salivary flow rate showed a decreasing 
trend. A positive correlation was found between OM and MUC5B, 
albumin and lactoferrin levels in SWS. Furthermore, due to protocol 
changes it was possible to observe the effect of cryotherapy on OM 
F IGURE  5 Mean ± 95% CI for unstimulated whole-mouth saliva (UWS) (a) and stimulated whole- mouth saliva (SWS) (b) pH of part A (grey 
lines) and part B (black lines). Numbers in the graphs represent the number of patients per time point for part A (grey) and part B (black). 
Significance levels are based on paired t tests with scaled scores all compared to day −3, *p < .05, **p < .01
(a) (b)
F IGURE  6 Mean ± 95% CI of total protein concentration in unstimulated whole-mouth saliva (UWS) (a) and stimulated whole- mouth saliva 
(SWS) (b) for part A (grey lines) and part B (black lines). Numbers in the graphs represent the number of patients per time point for part A (grey) 
and part B (black). Significance levels are based on paired t tests with scaled scores all compared to day −3, *p < 0.05, **p < 0.01, ***p < .001
(a) (b)
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development, which resulted in significantly lower max OMNI scores 
during the whole study period in the second part with cryotherapy.
Consistent with the published literature, peak OM was reached 
around day 7 and had almost returned to baseline at the end of the 
study period (Blijlevens et al., 2008). Oral mucositis caused by HDM 
was reduced by the use of cryotherapy in this study. As melphalan 
is found in saliva, the local vasoconstriction caused by the cryother-
apy may reduce the melphalan concentration in saliva (Epstein et al., 
2002; Slavik, Wu, & Riley, 1993). Similar to a retrospective study, 
cryotherapy resulted in reduced OM, but did not reduce the dura-
tion of OM (Batlle et al., 2014).
Although a direct effect of HDM on salivary glands is unclear, 
conditioning therapy before HSCT causes salivary hypofunction 
(Epstein et al., 2002). Furthermore, salivary gland dysfunction by 
lymphocyte infiltration is found using gland biopsies and a scinti-
graphic method several weeks after HSCT with conditioning reg-
imens consisting of cyclophosphamide, busulfan and TBI (Coracin 
et al., 2006; Lindahl, Lönnquist, & Hedfors, 1988). Most other 
studies measuring salivary flow rate after HSCT found a decrease 
in salivary flow rate (Amaral et al., 2012; Avivi et al., 2009; Boer, 
Correa, Tenuta, Souza, & Vigorito, 2015; Elad et al., 2006; Nagler, 
Barness- Hadar, Lieba, & Nagler, 2006). However, one study found 
no changes in UWS flow rate in autologous HSCT patients, while a 
study in allogeneic patients showed an increase in UWS flow rate 
8- 10 days after HSCT (Avivi et al., 2009; Boer et al., 2015). This 
increase might be related to dysphagia resulting in an increased 
resting volume of saliva as suggested by the authors (Boer et al., 
2015).
One indication for glandular dysfunction caused by HDM is the 
similar decrease in flow rate and pH at day 4 in this study. However, 
the protein secretory functions of the glands are not affected as sug-
gested by the increase in total protein and lactoferrin. Lactoferrin 
in saliva has a glandular origin although it is also a product of PMNs 
(Reitamo, Konttinen, & Segerberg- Konttinen, 1980). The increase in 
lactoferrin observed in this study may be derived from glandular ori-
gin as the PMN levels in blood decrease after HSCT resulting in neu-
tropenia. To further investigate protein output of the salivary glands, 
salivary amylase levels could be studied or glandular saliva could be 
used to determine changes in specific glandular- derived proteins.
Myeloperoxidase is secreted by PMNs and could therefore be 
used as an indirect measurement of the PMN levels in saliva. The de-
crease in MPO found in this study at day 7 probably reflects neutro-
penia. Interestingly, the MPO levels in saliva showed an increasing 
trend some days before the PMNs were again detectable in blood. 
This finding is supported by two other studies measuring PMN lev-
els directly after HSCT and may indicate that PMNs from the stem 
cells directly reach the site of inflammation before they circulate at 
detectable levels in blood (Lieschke et al., 1992; Pink et al., 2009).
F IGURE  7 Differences in unstimulated whole-mouth saliva (UWS) and stimulated whole- mouth saliva (SWS) MUC5B and albumin. 
(a) Example of a Coomassie Brilliant Blue (CBB)- and Periodic Acid- Schiff (PAS)- stained gel and Western blots for MUC5B and albumin of 
one representative patient. Mean ± 95% CI of scaled scores of MUC5B (b) and albumin (c) levels in UWS (black lines) and SWS (grey lines). 
Numbers in the graphs represent the number of patients per time point for UWS (black) and SWS (grey). Significance levels are based on 
paired t tests with scaled scores compared to day −3. *p < .05, **p < .01. (d) Mean ± SD of albumin concentration in blood for part A (grey 
line) and part B (black line), numbers in the graph represent the number of patients per time point for part A (grey) and part B (black) [Colour 
figure can be viewed at wileyonlinelibrary.com]
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Besides a decreasing trend in salivary flow rate, a decrease in sal-
ivary antimicrobial defence is also described in the literature mainly 
by a decrease in total or secretory IgA levels after HSCT (Avivi et al., 
2009; Chaushu et al., 1994; Dens et al., 1996; Norhagen- Engstrom, 
Hammarstrom, Lonnqvist, Soder, & Smith, 1988). One mechanism 
to overcome this decreased antimicrobial defence might be an in-
creased secretion of lactoferrin as most salivary proteins act in 
synergy for the antimicrobial function (Avivi et al., 2009; Imanguli 
et al., 2007). This hypothesis is supported in our study by a de-
creasing trend in total IgA levels and increased levels of lactofer-
rin. Furthermore, the increase in lactoferrin and albumin levels was 
also positively correlated with OM. Salivary albumin levels were in-
creased during peak OM, while blood levels of albumin show a de-
creasing trend. This supports the previously described hypothesis of 
decreased integrity of the oral mucosa, which may result in leakage 
of blood substances into saliva during OM (Avivi et al., 2009; Izutsu 
et al., 1981).
Another OM- related complaint after HSCT is xerostomia, the 
feeling of a dry mouth. As suggested by the dryness component of 
the OMNI score, xerostomia was present during the whole study pe-
riod. Xerostomia has been linked to changes in the lubricating pro-
tein MUC5B (Chaudhury, Shirlaw, Pramanik, Carpenter, & Proctor, 
2015; Dijkema et al., 2012). The dryness component of the OMNI 
score was negatively correlated with UWS flow rate and, although 
no significant changes in MUC5B concentrations were observed, 
positively correlated with SWS MUC5B levels. This counterintuitive 
finding is supported by another study where patients with xerosto-
mia had similar or higher MUC5B and MUC7 concentrations, com-
bined with differences in the glycosylation of the mucins (Chaudhury 
et al., 2015). We conclude that the correlation may be based on re-
duced total MUC5B availability or changed lubricating capabilities 
of the mucins.
The differences in the levels of proteins between UWS and SWS 
found in this study can be explained by the normal composition of 
F IGURE  8 Mean ± 95% CI of absolute values of total IgA (a), lactoferrin (b) and myeloperoxidase (c) levels in unstimulated whole-mouth 
saliva (UWS) (black lines) and stimulated whole- mouth saliva (SWS) (grey lines). Numbers in the graphs represent the number of patients per 
time point for UWS (black) and SWS (grey). Significance levels are based on paired t tests with scaled scores all compared to day −3, *p < .05, 
**p < .01 and ***p < .001. (d) Mean ± SD of blood levels of polymorphonuclear leucocytes (PMNs) over time for part A (grey line) and part B 
(black line), numbers in the graph represent the number of patients per time point for part A (grey) and part B (black)
(a) (c)
(b) (d)
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UWS and SWS. In resting conditions, saliva is mainly formed by se-
cretions from the submandibular and sublingual glands. In stimulated 
saliva, the parotid gland contributes more, which results in more wa-
tery saliva compared to UWS (Proctor, 2016).
One limitation of several studies evaluating salivary changes in 
HSCT recipients is the mixed patient population. Only one earlier 
study evaluated early salivary changes in a homogenous group of 
MM patients receiving HDM and autologous HSCT (Avivi et al., 
2009). Our observational study also included a homogenous patient 
population. However, both studies included small numbers of pa-
tients and lost power due to missing samples caused by nausea and 
hyposalivation especially during the OM period. Furthermore, due 
to logistic difficulties it was not possible to collect saliva at the same 
day during the whole study period. It was tried to collect saliva at the 
same time per patients, but also due to logistic difficulties, this was 
not always possible.
Salivary changes may influence the severity of OM. For proper 
symptom management, local salivary changes may be indicative. 
This study found decreased total IgA levels in saliva resulting in de-
creased antimicrobial defence, which may be compensated by other 
antimicrobial proteins in saliva such as lactoferrin. However, further 
research is necessary to confirm and expand these results.
In conclusion, our observational study showed compositional 
changes in saliva reflecting inflammation of the salivary glands and 
the oral mucosae in the first days after autologous HSCT, of which 
the changes in albumin and lactoferrin were correlated with OM 
development. Although cryotherapy in the second study resulted 
in decreased OM severity, both studies showed similar trends in al-
tered salivary protein composition.
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